The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis

Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ashrafi, Sadra [verfasserIn] Hatami, Hossein Bidhendi-Yarandi, Razieh Panahi, Mohammad Hossein

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2024

Schlagwörter:	COVID-19 Thyroid disorders Prevalence Systematic review Meta-analysis

Anmerkung:	© The Author(s) 2023

Übergeordnetes Werk:	Enthalten in: BMC endocrine disorders - [S.l.] : BioMed Central, 2001, 24(2024), 1 vom: 02. Jan.
Übergeordnetes Werk:	volume:24 ; year:2024 ; number:1 ; day:02 ; month:01

Links:	Volltext

DOI / URN:	10.1186/s12902-023-01534-9

Katalog-ID:	SPR054231299

Internformat


LEADER	01000naa a22002652 4500
001	SPR054231299
003	DE-627
005	20240103064902.0
007	cr uuu---uuuuu
008	240103s2024 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/s12902-023-01534-9 \|2 doi
035			\|a (DE-627)SPR054231299
035			\|a (SPR)s12902-023-01534-9-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Ashrafi, Sadra \|e verfasserin \|4 aut
245	1	4	\|a The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis
264		1	\|c 2024
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s) 2023
520			\|a Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601.
650		4	\|a COVID-19 \|7 (dpeaa)DE-He213
650		4	\|a Thyroid disorders \|7 (dpeaa)DE-He213
650		4	\|a Prevalence \|7 (dpeaa)DE-He213
650		4	\|a Systematic review \|7 (dpeaa)DE-He213
650		4	\|a Meta-analysis \|7 (dpeaa)DE-He213
700	1		\|a Hatami, Hossein \|4 aut
700	1		\|a Bidhendi-Yarandi, Razieh \|4 aut
700	1		\|a Panahi, Mohammad Hossein \|4 aut
773	0	8	\|i Enthalten in \|t BMC endocrine disorders \|d [S.l.] : BioMed Central, 2001 \|g 24(2024), 1 vom: 02. Jan. \|w (DE-627)355456575 \|w (DE-600)2091323-0 \|x 1472-6823 \|7 nnns
773	1	8	\|g volume:24 \|g year:2024 \|g number:1 \|g day:02 \|g month:01
856	4	0	\|u https://dx.doi.org/10.1186/s12902-023-01534-9 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 24 \|j 2024 \|e 1 \|b 02 \|c 01

Indexfelder

author_variant	s a sa h h hh r b y rby m h p mh mhp
matchkey_str	article:14726823:2024----::hpeaecotyodiodricvd9ainssseair
hierarchy_sort_str	2024
publishDate	2024
allfields	10.1186/s12902-023-01534-9 doi (DE-627)SPR054231299 (SPR)s12902-023-01534-9-e DE-627 ger DE-627 rakwb eng Ashrafi, Sadra verfasserin aut The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601. COVID-19 (dpeaa)DE-He213 Thyroid disorders (dpeaa)DE-He213 Prevalence (dpeaa)DE-He213 Systematic review (dpeaa)DE-He213 Meta-analysis (dpeaa)DE-He213 Hatami, Hossein aut Bidhendi-Yarandi, Razieh aut Panahi, Mohammad Hossein aut Enthalten in BMC endocrine disorders [S.l.] : BioMed Central, 2001 24(2024), 1 vom: 02. Jan. (DE-627)355456575 (DE-600)2091323-0 1472-6823 nnns volume:24 year:2024 number:1 day:02 month:01 https://dx.doi.org/10.1186/s12902-023-01534-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2024 1 02 01
spelling	10.1186/s12902-023-01534-9 doi (DE-627)SPR054231299 (SPR)s12902-023-01534-9-e DE-627 ger DE-627 rakwb eng Ashrafi, Sadra verfasserin aut The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601. COVID-19 (dpeaa)DE-He213 Thyroid disorders (dpeaa)DE-He213 Prevalence (dpeaa)DE-He213 Systematic review (dpeaa)DE-He213 Meta-analysis (dpeaa)DE-He213 Hatami, Hossein aut Bidhendi-Yarandi, Razieh aut Panahi, Mohammad Hossein aut Enthalten in BMC endocrine disorders [S.l.] : BioMed Central, 2001 24(2024), 1 vom: 02. Jan. (DE-627)355456575 (DE-600)2091323-0 1472-6823 nnns volume:24 year:2024 number:1 day:02 month:01 https://dx.doi.org/10.1186/s12902-023-01534-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2024 1 02 01
allfields_unstemmed	10.1186/s12902-023-01534-9 doi (DE-627)SPR054231299 (SPR)s12902-023-01534-9-e DE-627 ger DE-627 rakwb eng Ashrafi, Sadra verfasserin aut The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601. COVID-19 (dpeaa)DE-He213 Thyroid disorders (dpeaa)DE-He213 Prevalence (dpeaa)DE-He213 Systematic review (dpeaa)DE-He213 Meta-analysis (dpeaa)DE-He213 Hatami, Hossein aut Bidhendi-Yarandi, Razieh aut Panahi, Mohammad Hossein aut Enthalten in BMC endocrine disorders [S.l.] : BioMed Central, 2001 24(2024), 1 vom: 02. Jan. (DE-627)355456575 (DE-600)2091323-0 1472-6823 nnns volume:24 year:2024 number:1 day:02 month:01 https://dx.doi.org/10.1186/s12902-023-01534-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2024 1 02 01
allfieldsGer	10.1186/s12902-023-01534-9 doi (DE-627)SPR054231299 (SPR)s12902-023-01534-9-e DE-627 ger DE-627 rakwb eng Ashrafi, Sadra verfasserin aut The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601. COVID-19 (dpeaa)DE-He213 Thyroid disorders (dpeaa)DE-He213 Prevalence (dpeaa)DE-He213 Systematic review (dpeaa)DE-He213 Meta-analysis (dpeaa)DE-He213 Hatami, Hossein aut Bidhendi-Yarandi, Razieh aut Panahi, Mohammad Hossein aut Enthalten in BMC endocrine disorders [S.l.] : BioMed Central, 2001 24(2024), 1 vom: 02. Jan. (DE-627)355456575 (DE-600)2091323-0 1472-6823 nnns volume:24 year:2024 number:1 day:02 month:01 https://dx.doi.org/10.1186/s12902-023-01534-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2024 1 02 01
allfieldsSound	10.1186/s12902-023-01534-9 doi (DE-627)SPR054231299 (SPR)s12902-023-01534-9-e DE-627 ger DE-627 rakwb eng Ashrafi, Sadra verfasserin aut The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2023 Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601. COVID-19 (dpeaa)DE-He213 Thyroid disorders (dpeaa)DE-He213 Prevalence (dpeaa)DE-He213 Systematic review (dpeaa)DE-He213 Meta-analysis (dpeaa)DE-He213 Hatami, Hossein aut Bidhendi-Yarandi, Razieh aut Panahi, Mohammad Hossein aut Enthalten in BMC endocrine disorders [S.l.] : BioMed Central, 2001 24(2024), 1 vom: 02. Jan. (DE-627)355456575 (DE-600)2091323-0 1472-6823 nnns volume:24 year:2024 number:1 day:02 month:01 https://dx.doi.org/10.1186/s12902-023-01534-9 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 24 2024 1 02 01
language	English
source	Enthalten in BMC endocrine disorders 24(2024), 1 vom: 02. Jan. volume:24 year:2024 number:1 day:02 month:01
sourceStr	Enthalten in BMC endocrine disorders 24(2024), 1 vom: 02. Jan. volume:24 year:2024 number:1 day:02 month:01
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	COVID-19 Thyroid disorders Prevalence Systematic review Meta-analysis
isfreeaccess_bool	true
container_title	BMC endocrine disorders
authorswithroles_txt_mv	Ashrafi, Sadra @@aut@@ Hatami, Hossein @@aut@@ Bidhendi-Yarandi, Razieh @@aut@@ Panahi, Mohammad Hossein @@aut@@
publishDateDaySort_date	2024-01-02T00:00:00Z
hierarchy_top_id	355456575
id	SPR054231299
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR054231299</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240103064902.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240103s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12902-023-01534-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR054231299</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12902-023-01534-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ashrafi, Sadra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">COVID-19</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thyroid disorders</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prevalence</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systematic review</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Meta-analysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hatami, Hossein</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bidhendi-Yarandi, Razieh</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Panahi, Mohammad Hossein</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC endocrine disorders</subfield><subfield code="d">[S.l.] : BioMed Central, 2001</subfield><subfield code="g">24(2024), 1 vom: 02. Jan.</subfield><subfield code="w">(DE-627)355456575</subfield><subfield code="w">(DE-600)2091323-0</subfield><subfield code="x">1472-6823</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">day:02</subfield><subfield code="g">month:01</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12902-023-01534-9</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="b">02</subfield><subfield code="c">01</subfield></datafield></record></collection>
author	Ashrafi, Sadra
spellingShingle	Ashrafi, Sadra misc COVID-19 misc Thyroid disorders misc Prevalence misc Systematic review misc Meta-analysis The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis
authorStr	Ashrafi, Sadra
ppnlink_with_tag_str_mv	@@773@@(DE-627)355456575
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1472-6823
topic_title	The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis COVID-19 (dpeaa)DE-He213 Thyroid disorders (dpeaa)DE-He213 Prevalence (dpeaa)DE-He213 Systematic review (dpeaa)DE-He213 Meta-analysis (dpeaa)DE-He213
topic	misc COVID-19 misc Thyroid disorders misc Prevalence misc Systematic review misc Meta-analysis
topic_unstemmed	misc COVID-19 misc Thyroid disorders misc Prevalence misc Systematic review misc Meta-analysis
topic_browse	misc COVID-19 misc Thyroid disorders misc Prevalence misc Systematic review misc Meta-analysis
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	BMC endocrine disorders
hierarchy_parent_id	355456575
hierarchy_top_title	BMC endocrine disorders
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)355456575 (DE-600)2091323-0
title	The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis
ctrlnum	(DE-627)SPR054231299 (SPR)s12902-023-01534-9-e
title_full	The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis
author_sort	Ashrafi, Sadra
journal	BMC endocrine disorders
journalStr	BMC endocrine disorders
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2024
contenttype_str_mv	txt
author_browse	Ashrafi, Sadra Hatami, Hossein Bidhendi-Yarandi, Razieh Panahi, Mohammad Hossein
container_volume	24
format_se	Elektronische Aufsätze
author-letter	Ashrafi, Sadra
doi_str_mv	10.1186/s12902-023-01534-9
title_sort	prevalence of thyroid disorders in covid-19 patients: a systematic review and meta-analysis
title_auth	The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis
abstract	Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601. © The Author(s) 2023
abstractGer	Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601. © The Author(s) 2023
abstract_unstemmed	Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601. © The Author(s) 2023
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis
url	https://dx.doi.org/10.1186/s12902-023-01534-9
remote_bool	true
author2	Hatami, Hossein Bidhendi-Yarandi, Razieh Panahi, Mohammad Hossein
author2Str	Hatami, Hossein Bidhendi-Yarandi, Razieh Panahi, Mohammad Hossein
ppnlink	355456575
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/s12902-023-01534-9
up_date	2024-07-04T00:35:39.982Z
_version_	1803606651026014208
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR054231299</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240103064902.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240103s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12902-023-01534-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR054231299</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12902-023-01534-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ashrafi, Sadra</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration PROSPERO CRD42022312601.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">COVID-19</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thyroid disorders</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prevalence</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systematic review</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Meta-analysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hatami, Hossein</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bidhendi-Yarandi, Razieh</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Panahi, Mohammad Hossein</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC endocrine disorders</subfield><subfield code="d">[S.l.] : BioMed Central, 2001</subfield><subfield code="g">24(2024), 1 vom: 02. Jan.</subfield><subfield code="w">(DE-627)355456575</subfield><subfield code="w">(DE-600)2091323-0</subfield><subfield code="x">1472-6823</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">day:02</subfield><subfield code="g">month:01</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12902-023-01534-9</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="b">02</subfield><subfield code="c">01</subfield></datafield></record></collection>
score	7.3998623

Nicht das Richtige dabei?

Schreiben Sie uns!

The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?